The US healthcare reform contains several positives for the industry, writes Samuel Isaly of Finsbury Worldwide Pharmaceutical Trust.
The pharmaceutical industry crossed a major milestone and investors in the sector breathed a sigh of relief when the US healthcare reform was signed on March 2010. The final version of reform contains several positives for the industry, such as 12 years of exclusivity for newly-approved biotech drugs. Having 32 million more lives covered should benefit both pharmaceutical and biotech companies as they enjoy increased demand for their products. This boost to volumes should outweigh any pricing pressure. Disappointing 2009 After stellar returns in 2008, when the pharmaceutical sector ...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
